[{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Cell Therapy Group \/ Baize Plan Fund"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus DMCC"},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ysios Capital"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences Pte ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bioscience \/ SRS Life Sciences Pte ltd"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC)...

                          Product Name : LTX-608

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 15, 2021

                          Lead Product(s) : Nafamostat

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : AcelRx Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 15, 2021

                          Lead Product(s) : Enoxaparin Sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Premier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 06, 2020

                          Lead Product(s) : Abelacimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Anthos Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.

                          Product Name : BioFe

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 13, 2020

                          Lead Product(s) : FTH1

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : SRS Life Sciences Pte ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.

                          Product Name : VMX-C001

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          August 07, 2020

                          Lead Product(s) : VMX-C001

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Ysios Capital

                          Deal Size : $36.6 million

                          Deal Type : Series B Financing

                          blank

                          06

                          Shanghai Cell Therapy Group

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Shanghai Cell Therapy Group

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 28, 2020

                          Lead Product(s) : Hematopoietic Stem Cell

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Baize Plan Fund

                          Deal Size : $3.6 million

                          Deal Type : Collaboration

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 29, 2020

                          Lead Product(s) : Heparin Sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Undisclosed

                          Sponsor : Cerus DMCC

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank